Optimisation of patient-reported outcome measurement for haematological cancer patients receiving novel immunotherapies: perspectives of multi-stakeholders - Report - MDSpire
Advertisement
Optimisation of patient-reported outcome measurement for haematological cancer patients receiving novel immunotherapies: perspectives of multi-stakeholders
Clinical Report: Enhancing Patient-Reported Outcome Measures for Hematological Cancer Patients
Overview
This report explores the challenges and opportunities in implementing patient-reported outcome measures (PROMs) for patients with hematological cancers undergoing CAR-T and BsAbs therapies. It highlights the need for improved alignment and interpretability of PROM data to enhance patient care.
Background
The integration of patient-reported outcomes (PROMs) in clinical trials is essential for understanding the impact of innovative therapies like CAR-T and BsAbs on patients' quality of life. These therapies, while promising, can lead to significant side effects that are not always captured by traditional clinical measures. Addressing the complexities of PROM implementation can improve patient-centered care and inform treatment decisions.
Data Highlights
No numerical data presented in the article.
Key Findings
38 individuals participated in focus groups and interviews regarding PROMs in hematological cancers.
Challenges include logistical issues post-CAR-T infusion and varying side effects from BsAbs.
Only 27% of CAR-T trials currently utilize PROMs, indicating a gap in patient experience assessment.
Clear guidance on PROM implementation is necessary for capturing treatment-related side effects effectively.
Early and frequent assessments of patient-important domains are recommended for better data collection.
Clinical Implications
Healthcare professionals should prioritize the integration of PROMs in clinical trials for hematological cancers to capture the full spectrum of patient experiences. Enhanced understanding of treatment-related side effects can lead to improved patient management and support.
Conclusion
The findings underscore the importance of optimizing PROM use in clinical settings to better reflect patient experiences with CAR-T and BsAbs therapies. Improved PROM strategies can significantly enhance patient care and inform clinical decision-making.
